ImageneBio (IMA) Q2 2026 earnings summary

Executive summary

• Completed a reverse merger with Ikena Oncology in July 2025, divesting non-OX40 assets and focusing solely on the clinical development of IMG-007 (olevaprubart), a non-depleting anti-OX40 monoclonal antibody for immunological, autoimmune, and inflammatory diseases.

• Advanced clinical development of olevaprubart (IMG-007), with an ongoing multi-country Phase 2b ADAPTIVE trial in atopic dermatitis and a planned Phase 2 trial in alopecia areata for 2026.

• Opened a long-term extension study for ADAPTIVE trial participants and received a positive safety review from the Independent Data Monitoring Committee.

• Strengthened leadership with new CFO and General Counsel appointments; closed a $30 million private placement in April 2026.

• Completed the divestiture of non-OX40 assets to Miragene Inc., receiving a promissory note and establishing contingent value rights (CVRs) for legacy shareholders.

Financial highlights

• Net loss for the six months ended June 30, 2026 was $20.8 million, compared to $13.7 million for the same period in 2025.

• Research and development expenses increased to $12.6 million (from $9.7 million year-over-year), driven by higher clinical trial costs and compensation.

• General and administrative expenses rose to $11.2 million (from $4.5 million year-over-year), reflecting higher personnel, stock-based compensation, legal, and facilities costs.

• Cash, cash equivalents, and marketable securities totaled $136.2 million as of June 30, 2026, expected to fund operations into Q1 2028.

• Net loss per share (basic and diluted) for Q2 2026 was $0.63, with weighted-average shares outstanding at 16.2 million.

Outlook and guidance

• Current cash resources are expected to fund operations for at least the next 12 months and projected to support planned operations into Q1 2028.

• Topline data from the Phase 2b ADAPTIVE trial in atopic dermatitis anticipated in Q4 2027; initial alopecia areata Phase 2 data expected in 2028.

• Substantial additional funding will be required to advance clinical programs, seek regulatory approval, and prepare for commercialization.